Fluid Biopsy for the Diagnosis of Lung Cancer

Study summary

This trial collects and studies blood samples via fluid biopsy for the diagnosis of lung cancer. Studying blood samples in the laboratory may help doctors develop a blood test for lung cancer in the future and provide a better way to screen patients for lung cancer.

Ask AI to explain this study

Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedBiospecimen Collection and Laboratory Biomarker Analysis

Plus 2 other study approaches.

Who it may be forLung Carcinoma

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 5, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?2 U.S. locations

Locations may change over time.

Who runs it?University of Southern California

Study sponsor

Study overview

What this study is about

Purpose: Not specified
Study type: Observational
Phase: Not applicable
Sponsor: University of Southern California
Interventions being studied: Procedure: Biospecimen Collection; Other: Laboratory Biomarker Analysis; Procedure: Liquid Biopsy; Other: Medical Chart Review

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Scheduled to undergo a diagnostic biopsy for possible lung cancer or
Completed a diagnostic lung cancer biopsy in the prior 2 weeks and has not yet undergone treatment or
Planning or completed in the last 2 weeks a CT lung cancer screen
Ability to understand and the willingness to sign a written informed consent

Reasons someone may not be able to joinExclusion criteria

Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study
Known other solid tumor malignancy other than lung cancer requiring ongoing active treatment

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Los Angeles County-USC Medical CenterLos Angeles, California
USC / Norris Comprehensive Cancer CenterLos Angeles, California

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 5, 2025. Always confirm current availability with the study team.

View original record ↗